Released on = March 15, 2007, 9:20 am

Press Release Author = Bio3 Research S.r.l.

Industry = Biotech

Press Release Summary = Bio3 Research S.r.l., Milan - Italy, has been granted by the
Australian Patent Office a patent in the field of cardiovascular diseases related to
HMGB1 over-expression and for the use of HMGB1 protein in connective tissue
regeneration

Press Release Body = MILANO, Italy, March 15, 2007 - Bio3 Research S.r.l. announced
today that the Australian Patent Office has granted the company the patent in the
HMGB1 (High Mobility Group Box 1 protein) field which entitles the use of antagonist
molecules (Mabs and their fragments, Small Molecules inhibitors and antagonist
molecules having sequence homology with HMG Box) that can bind the functional HMG
Box binding domain of the receptor RAGE for the preparation of therapeutic agents
for the treatment of vascular diseases, such as Atherosclerosis and Restenosis.
Furthermore, the granted patent entitles Bio3 Research to utilize HMGB1 as such and
its fragments for the preparation of therapeutic agents which facilitate and/or
induce Connective Tissue Regeneration.

Mr. Francesco Paolo Pilato, CEO Bio3 Research S.r.l., said: "We are very pleased for
the Australian PO decision to grant the company said patent, which comes on the top
of the already granted patent in Italy. Said patent entitles the company or licensed
third parties the use of HMGB1 antagonists to treat cardiovascular disorders and to
develop drugs based on HMGB1 as such and its fragments in the regeneration of
damaged tissues. Remarkable scientific contribution has come from the studies
conducted by Prof. Marco E. Bianchi (Inventor) an Associate Scientist of Bio3
Research. We strongly believe that the Pharmaceutical environment will soon consider
HMGB1 as an innovative biological target for the development of drugs to prevent
atherosclerotic plaque progression and restenosis after angioplasty. We are also
very keen to develop treatments based on the use of HMGB1 as such, to regenerate
damaged connective tissues. Preliminary animal data in cartilage repair are
encouraging Bio3 Research to proceed further, and extend researches to bone matrix
reconstitution and wound healing. We anticipate with much pleasure that soon patents
will be also granted in other countries."

About Bio3 Research S.r.l.
Bio3 Research S.r.l., an Italian company founded in 2001, has headquarters in Milan
and an office at the Bioindustry Park of Canavese (Turin). Bio3 Research works with
research institutions, individual scientists and early-stage companies to identify,
protect and exploit commercially promising intellectual property in the life
sciences. Such assistance may include pre-clinical development and negotiation of
strategic industrial partnerships. Bio3 Research's activity focuses mainly on the
field of HMBG1-related cardiovascular disorders and use of HMGB1 and its fragments
in connective tissue regeneration. Other fields of interest include skin and renal
diseases. Additional information on Bio3 Research can be obtained from
www.bio3research.com


Web Site = http://www.bio3research.com

Contact Details = Bio3 Research S.r.l.
Via della Moscova 6/8
20121 Milano
Italy